TY - JOUR
T1 - Oesophageal atresia
AU - van Lennep, Marinde
AU - Singendonk, Maartje M. J.
AU - Dall’Oglio, Luigi
AU - Gottrand, Fréderic
AU - Krishnan, Usha
AU - Terheggen-Lagro, Suzanne W. J.
AU - Omari, Taher I.
AU - Benninga, Marc A.
AU - van Wijk, Michiel P.
PY - 2019/4/18
Y1 - 2019/4/18
N2 - Oesophageal atresia (EA) is a congenital abnormality of the oesophagus that is caused by incomplete embryonic compartmentalization of the foregut. EA commonly occurs with a tracheo-oesophageal fistula (TEF). Associated birth defects or anomalies, such as VACTERL association, trisomy 18 or 21 and CHARGE syndrome, occur in the majority of patients born with EA. Although several studies have revealed signalling pathways and genes potentially involved in the development of EA, our understanding of the pathophysiology of EA lags behind the improvements in surgical and clinical care of patients born with this anomaly. EA is treated surgically to restore the oesophageal interruption and, if present, ligate and divide the TEF. Survival is now ~90% in those born with EA with severe associated anomalies and even higher in those born with EA alone. Despite these achievements, long-term gastrointestinal and respiratory complications and comorbidities in patients born with EA are common and lead to decreased quality of life. Oesophageal motility disorders are probably ubiquitous in patients after undergoing EA repair and often underlie these complications and comorbidities. The implementation of several new diagnostic and screening tools in clinical care, including high-resolution impedance manometry, pH-multichannel intraluminal impedance testing and disease-specific quality of life questionnaires now provide better insight into these problems and may contribute to better long-term outcomes in the future.
AB - Oesophageal atresia (EA) is a congenital abnormality of the oesophagus that is caused by incomplete embryonic compartmentalization of the foregut. EA commonly occurs with a tracheo-oesophageal fistula (TEF). Associated birth defects or anomalies, such as VACTERL association, trisomy 18 or 21 and CHARGE syndrome, occur in the majority of patients born with EA. Although several studies have revealed signalling pathways and genes potentially involved in the development of EA, our understanding of the pathophysiology of EA lags behind the improvements in surgical and clinical care of patients born with this anomaly. EA is treated surgically to restore the oesophageal interruption and, if present, ligate and divide the TEF. Survival is now ~90% in those born with EA with severe associated anomalies and even higher in those born with EA alone. Despite these achievements, long-term gastrointestinal and respiratory complications and comorbidities in patients born with EA are common and lead to decreased quality of life. Oesophageal motility disorders are probably ubiquitous in patients after undergoing EA repair and often underlie these complications and comorbidities. The implementation of several new diagnostic and screening tools in clinical care, including high-resolution impedance manometry, pH-multichannel intraluminal impedance testing and disease-specific quality of life questionnaires now provide better insight into these problems and may contribute to better long-term outcomes in the future.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064531257&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31000707
U2 - https://doi.org/10.1038/s41572-019-0077-0
DO - https://doi.org/10.1038/s41572-019-0077-0
M3 - Review article
C2 - 31000707
SN - 2056-676X
VL - 5
SP - 26
JO - NATURE REVIEWS DISEASE PRIMERS
JF - NATURE REVIEWS DISEASE PRIMERS
IS - 1
M1 - 26
ER -